ERS International Congress 2016 - Poster Discussion Lung cancer and immune cells: friends or foes?

Poster Discussion

Lung cancer and immune cells: friends or foes?

Chairs

Berlin (Germany)

Golnik (Slovenia)

Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer H. Cherif(Tunis, Tunisia)

The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer P. Yıldız(Istanbul, Turkey)

Correlation of IL-17A concentration with T regulatory cells in lung cancer microenvironment J. Domagała-Kulawik(Warszawa, Poland)

Feroptosis of alveolar macrophages in lung cancer S. Zunic(Beograd, Republic of Serbia)

CD163 and CCR7 markers for macrophage polarisation in patients with lung cancer J. Domagała-Kulawik(Warszawa, Poland)

Interleukin 27 (IL27) as antitumor tool? Results from bronchoalveolar lavage (BAL) examination T. Wandtke(Bydgoszcz, Poland)

Pro and anti-inflammatory cytokines in patients with lung adenocarcinoma clinical stages IIIB and IV undergoing chemotherapy U. Rumbo Nava(Mexico, Mexico)

Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer S. Bacha(Ariana, Tunisia)

COPD-like inflammation drives the progression of K-ras induced early cancerous lesions C. Jungnickel(Homburg, Germany)

The oppositedirection of LC3 A/B-I/II change in Raw264.7 cells and A549 cells treated with graphene oxide and its functionalized chemicals J. Shin(Seoul, Republic of Korea)

cAMP-response element binding protein in KRAS-driven lung adenocarcinoma G. Giotopoulou(Munich, Germany)

Bone marrow-derived mesenchymal stem cells involve in lymphangiogenesis of lung cancer X. Zhou(Nanjing, China)

Dihydroartemisinin combined with cisplatinum induced apoptosis and related mechanism research in human lung adenocarcinoma H1299 cells X. Yin(Qinhuangdao (Hebei), China)

CellCollector®: A novel method for the isolation of circulating tumor cells (CTC) in vivo and ex vivo in lung cancer patients during therapy B. Schmidt(Berlin, Germany)